Document is current
Any future updates will be listed below
-
Authors
Curran, Ashley M. https://orcid.org/0000-0001-7735-0437
Girgis, Alexander A. https://orcid.org/0000-0002-4706-5480
Jang, Yura
Crawford, Jonathan D. https://orcid.org/0000-0001-7614-9424
Thomas, Mekha A. https://orcid.org/0000-0002-5169-6568
Kawalerski, Ryan
Coller, Jeff https://orcid.org/0000-0001-5662-8110
Bingham, Clifton O. III
Na, Chan Hyun https://orcid.org/0000-0002-3622-2938
Darrah, Erika https://orcid.org/0000-0003-1119-0279
-
Funding
Funding for this research was provided by:
Rheumatology Research Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR079404, P30-AR070254, P30-AR070254)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (S10OD021844, S10-OD021844)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
U.S. Department of Health & Human Services | NIH | NIH Office of the Director
- License Information
-
More Information
Article History
Received: 10 May 2022
Accepted: 6 February 2023
First Online: 24 February 2023
Competing interests
: The authors declare the following competing interests: E.D. is an inventor on a licensed patent (US patent no. 8,975,033) and licensed provisional patent (US patent no. 62/481,158) related to the use of antibodies to PAD3 and PAD2, respectively, in identifying clinically informative disease subsets in RA, and has received consulting fees from Celgene and Bristol Myers Squibb and research support from Pfizer, Celgene, and Bristol Myers Squibb outside of this work. The remaining authors declare no competing interests.
